Aurigene to Provide Cell Therapy Discovery Services to Edity Therapeutics

• Aurigene Pharmaceutical Services to provide cell therapy discovery services to Edity Therapeutics.

• The partnership aims to accelerate clinical development of novel cell therapy technologies.

Aurigene Pharmaceutical Services, an India-based contract research, development, and manufacturing organisation (CRO/CDMO), announced on 1 July 2024 that it will provide discovery services in cell therapy to Edity Therapeutics, an Israeli company. This collaboration is designed to support and speed up the clinical development of advanced and novel technologies.

The partnership builds on Aurigene’s established services in the discovery and development of advanced therapies, including antibodies, antibody-drug conjugates (ADCs), cell therapeutics, and viral vectors. This agreement follows an initial strategic collaboration between Edity and Aurigene’s parent company, Dr. Reddy’s Laboratories, which began in January 2024.

“We are delighted to add Edity to the growing list of global companies recognising Aurigene as a valued partner in the biologics and advanced therapies space,” said Roger Lias, PhD, global commercial head of biologics for Aurigene. “Our true end-to-end service offering from discovery through large-scale CGMP [current good manufacturing practice] manufacture allows us to efficiently deliver speed, unwavering quality and economically viable solutions to our customers as they bring much-needed therapeutics to patients.”

Edity has developed a unique immune cell delivery platform for selective intracellular delivery of therapeutic proteins, targeting cells with high specificity. The company has product candidates in oncology, gene therapy, autoimmune disorders, and regenerative medicine. In oncology, Edity focuses on addressing challenges in cell therapies for solid tumors, including antigen heterogeneity and tumor resistance.

“We are excited about the collaboration and look forward to working with Edity in building novel technologies,” said Aurigene CEO Akhil Ravi. “Edity’s cellular reprogramming technology to deliver therapeutic payloads to target cells adds a new mechanism to CAR-T based cell therapeutics with the potential to significantly increase efficacy.”

Edity’s earlier strategic collaboration with Dr. Reddy’s Laboratories aimed to create novel cell therapy medicines using Edity’s proprietary delivery platform. The new partnership with Aurigene aligns with Aurigene’s goal of cost-effective manufacturing of small molecules and biologics.

“We are thrilled to be working with Aurigene’s world-class team,” said Edity CEO Michal Golan Mashiach. “Their experience and breadth of technology offerings will help Edity to advance our pipeline and help patients with severe diseases. This collaboration will support our growth as we seek to create best-in-class medicines.”